2017 Hub Services report

Nature, as we’re told, abhors a vacuum. In the past, as new specialty pharmaceutical products came onto the market, a vacuum of sorts developed as healthcare providers (HCPs), pharmacists and the drugmakers themselves realized that the new drugs needed additional […]

Read More

Healthcare confronts opioid addiction

The slim hope that the growing opioid addiction crisis could be controlled by restricting access to prescription opioids—the abuse of which has been the starting point for many addicts—is slipping away as illegally manufactured opioid pills (some of them counterfeit […]

Read More

Pharma seeks growth in eyecare

Relative to other disease states, like cancer, diabetes or cardiovascular, ophthalmology is both smaller and less contentious. A relatively small number of pharma companies have significant franchises in it, namely, Allergan, Alcon (a subsidiary of Novartis) and Bausch + Lomb […]

Read More

Advancing the biopharma cold chain

With apologies to Rodgers and Hammerstein of Broadway musical fame, we can say that “biopharma cold chain is bustin’ out all over” in 2016. The steady stream of openings of dedicated, temperature-controlled warehouses and intermediate storage areas for biopharma products […]

Read More
| 1 Comment

When it Comes to Compliance, Learning Never Stops

Having the privilege to serve 
on the Alliance’s board affords me an enormous and gratifying experience, highlighted by the opportunity to participate in developing a new conference program each year. From the end of one year’s conference to the next, […]

Read More

2016 Product Security Report

For the moment, let’s all breathe a sigh of relief that no major counterfeiting scandal has erupted in the US in the past couple years; although there are always underpublicized cases of drug diversions or the improper purchase of prescription […]

Read More

Hub Services Special Report 2016

Market forces are driving pharma manufacturers and patients closer together—and now the pharma industry has a pathway with which to do this. The relationships are growing while pharma contends with regulatory constraints and the competing desires

Read More

The 2015 Biopharma Cold Chain Landscape

Fig. 1. Cold-chain drugs and biologics will outpace overall industry sales growth through 2019 Although dealing with rising cost pressures from payers around the world, the biopharma industry is enjoying strong growth, especially in the US. The long-sought promise of […]

Read More